By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Immunization and Public Health have been published. According to news reporting originating from Milan, Italy, by NewsRx correspondents, research stated, "The first-generation smallpox vaccine was based on live vaccinia virus (VV) and it successfully eradicated the disease worldwide. Therefore, it was not administered any more after 1980, as smallpox no longer existed as a natural infection."
Our news editors obtained a quote from the research from the University of Milan, "However, emerging threats by terrorist organisations has prompted new programmes for second-generation vaccine development based on attenuated VV strains, which have been shown to cause rare but serious adverse events in immunocompromised patients. Considering the closely related animal poxviruses that might also be used as bioweapons, and the increasing number of unvaccinated young people and AIDS-affected immunocompromised subjects, a safer and more effective smallpox vaccine is still required. New avipoxvirus-based vectors should improve the safety of conventional vaccines, and protect from newly emerging zoonotic orthopoxvirus diseases and from the threat of deliberate release of variola or monkeypox virus in a bioterrorist attack. In this study, DNA and fowlpox recombinants expressing the L1R, A27L, A33R and B5R genes were constructed and evaluated in a pre-clinical trial in mouse, following six prime/boost immunisation regimens, to compare their immunogenicity and protective efficacy against a challenge with the lethal VV IHD-J strain. Although higher numbers of VV-specific IFN-gamma-producing T lymphocytes were observed in the protected mice, the cytotoxic T-lymphocyte response and the presence of neutralising antibodies did not always correlate with protection."
According to the news editors, the research concluded: "In spite of previous successful results in mice, rabbits and monkeys, where SIV/HIV transgenes were expressed by the fowlpox vector, the immune response elicited by these recombinants was low, and most of the mice were not protected."
For more information on this research see: Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain. Virus Research, 2013;178(2):374-382. Virus Research can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Virus Research - www.elsevier.com/wps/product/cws_home/506054)
The news editors report that additional information may be obtained by contacting M. Bissa, Univ Milano Bicocca, Dept. of Biotechnol & Biosci, I-20126 Milan, Italy. Additional authors for this research include S.M. Pacchioni, C. Zanotto, C.D. Morghen, E. Illiano, F. Granucci, I. Zanoni, A. Broggi and A. Radaelli (see also Immunization and Public Health).
Keywords for this news article include: Milan, Italy, Drugs, Europe, Therapy, Vaccinia, Virology, Viral DNA, DNA Viruses, DNA Research, Viral Vaccines, Smallpox Vaccines, DNA Virus Infections, Poxviridae Infections, Immunization and Public Health
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC